Investigational Drug Information for Serelaxin
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Serelaxin?
Serelaxin is an investigational drug.
There have been 14 clinical trials for Serelaxin.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 31st 2014.
The most common disease conditions in clinical trials are Heart Failure, Liver Cirrhosis, and Hypertension, Portal. The leading clinical trial sponsors are Novartis Pharmaceuticals, Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, and NHS Lothian.
There are thirty-two US patents protecting this investigational drug and eight hundred and twenty international patents.
Summary for Serelaxin
| US Patents | 32 |
| International Patents | 820 |
| US Patent Applications | 134 |
| WIPO Patent Applications | 98 |
| Japanese Patent Applications | 46 |
| Clinical Trial Progress | Phase 3 (2014-01-31) |
| Vendors | 1 |
Recent Clinical Trials for Serelaxin
| Title | Sponsor | Phase |
|---|---|---|
| Serelaxin To Lower Portal Pressure | NHS Lothian | Phase 2 |
| Serelaxin To Lower Portal Pressure | Novartis Pharmaceuticals | Phase 2 |
| Serelaxin To Lower Portal Pressure | University of Edinburgh | Phase 2 |
Clinical Trial Summary for Serelaxin
Top disease conditions for Serelaxin
Top clinical trial sponsors for Serelaxin
US Patents for Serelaxin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Serelaxin | See Plans and Pricing | ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment | Madeleine Pharmaceuticals Pty Ltd. (Mount Barker, AU) | See Plans and Pricing |
| Serelaxin | See Plans and Pricing | sGC stimulators | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| Serelaxin | See Plans and Pricing | Modified relaxin B chain peptides | THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Parkville, Victoria, AU) | See Plans and Pricing |
| Serelaxin | See Plans and Pricing | Liquid pharmaceutical formulations for injection comprising yellow 5 or orange G and uses thereof | Eagle Biologics, Inc. (Woodcliff Lake, NJ) | See Plans and Pricing |
| Serelaxin | See Plans and Pricing | sGC stimulators | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Serelaxin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Serelaxin | Australia | AU2015230666 | 2034-04-09 | See Plans and Pricing |
| Serelaxin | Australia | AU2015230778 | 2034-04-09 | See Plans and Pricing |
| Serelaxin | European Patent Office | EP2968458 | 2033-03-15 | See Plans and Pricing |
| Serelaxin | European Patent Office | EP3116528 | 2033-03-15 | See Plans and Pricing |
| Serelaxin | World Intellectual Property Organization (WIPO) | WO2014138796 | 2033-03-15 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
